U.S. Stock Market Midday Update

Kala Bio rose 20.21%. Based on recent key news:

1. On June 16, Kala Bio's research and development focus in the field of gene editing is on ophthalmic diseases, and its gene therapy product line is expanding, aiming to address unmet medical needs. This news drove the stock price up, as the market holds an optimistic view of its future development prospects. Source: Zhitong Finance

2. On June 18, the value in the technology sector is rapidly shifting towards entities that can define standards, monopolize scarce resources, or create bilateral network effects. Kala Bio's advancements in gene editing technology position it favorably in this trend, further driving up the stock price. Source: Zhitong Finance. The prospects in the field of gene editing are broad but face challenges.

Stocks with High Trading Volume in the Industry

Amgen fell 1.66%, with increased trading volume. Based on recent key news:

1. On June 16, Mizuho raised Amgen's target price from $295 to $303. This move indicates analysts' optimistic outlook on Amgen's future performance, despite a short-term decline in stock price.

2. On June 16, Amgen's drug zasocitinib did not achieve the PASI 100 rate in psoriasis treatment compared to the test results of Skyrizi and Tremfya. Nevertheless, researchers believe that zasocitinib still has potential in the treatment of psoriasis and inflammatory bowel disease.

3. On June 17, multinational pharmaceutical companies adopted a "patent jungle strategy" in their patent layout to cope with the challenges of the patent cliff. This strategy may affect the market exclusivity and competitiveness of companies like Amgen. Patent strategies in the pharmaceutical industry impact market competition.

AbbVie fell 2.31%, with increased trading volume. Based on recent key news:

1. On June 16, the FDA approved AbbVie's Skinvive for reducing neck wrinkles. This approval marks the second indication for the product in the U.S., potentially enhancing the company's competitiveness in the beauty market.

2. On June 16, AbbVie's UZEDY® royalties grew strongly, but increased investment in innovation led to rising operating costs and net losses. This financial performance may affect investor confidence.

3. On June 17, AbbVie's sales of Skyrizi and Rinvoq grew by 31% and 23%, respectively, driving first-quarter revenue in 2026 to reach $15 billion. This growth demonstrates the company's strong performance in the new drug sector. High inflation increases the attractiveness of stable dividends.

CervoMed rose 81.63%. Based on recent key news:

1. On June 18, CervoMed received approval from the U.S. Patent and Trademark Office for a patent covering the use of neflamapimod in patients with pure Lewy body dementia, extending the protection period to 2042. The approval of this patent enhances market confidence in the company's future development, driving up the stock price

2. On June 17, CervoMed's stock price soared by 110%, primarily due to positive news regarding financing and clinical development updates. The company performed strongly in regular trading, with trading volume far exceeding average levels, indicating market optimism about its developments.

3. On June 16, CervoMed director Joshua S. Boger purchased 955,414 shares of common stock through a trust, demonstrating insider confidence in the company's prospects, further driving up the stock price. The biopharmaceutical industry has been quite volatile recently and requires attention.

Stocks Ranked Among the Top by Market Capitalization in the Industry

Gilead Sciences fell by 2.32%. Based on recent key news:

1. On June 15, the U.S. FDA accepted Gilead's application for the Yeztugo drug, which could become the first long-acting oral HIV prevention medication. This development could positively impact Gilead's market position, but the stock price still experienced a decline.

2. On June 15, Gilead's CFO sold 3,000 shares of common stock, which may raise market concerns about insider confidence in the company, leading to a drop in stock price.

3. On June 16, analyst ratings showed that Gilead was not included in the recommended buy list, despite its rating being moderate buy, which could affect investor confidence. The competition in the HIV drug market is intensifying and requires attention